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Abstract
Background: Several studies have investigated the impact of 7-valent pneumococcal conjugate vaccine (PCV7) on
pneumococcal (Sp) and staphylococcal (Sa) nasopharyngeal (NP) carriage. Few have investigated the impact on
Haemophilus influenzae (Hi) and Moraxella catarrhalis (Mc) carriage. We aimed to compare the NP carriage rates in
young children with acute otitis media (AOM) before and after PCV7 implementation in France.
Methods: Prior to PCV7 implementation, we performed 4 successive randomized trials with NP samples. These
studies compared several antibiotic regimens for treating AOM in young children (6 to 30 months). After PCV7
implementation, to assess the impact of the vaccination program on NP flora, young children with AOM were
enrolled in a prospective surveillance study. In each study, we obtained an NP sample to analyze the carriage rates
of Sp, Hi, Mc and Sa and the factors influencing the carriage. Standardized history and physical examination
findings were recorded; the methods used for NP swabs (sampling and cultures) were the same in all studies.
Results: We enrolled 4,405 children (mean age 13.9 months, median 12.8). Among the 2,598 children enrolled after
PCV7 implementation, 98.3% were vaccinated with PCV7. In comparing the pre- and post-PCV7 periods, we found
a slight but non-significant decrease in carriage rates of pneumococcus (AOR = 0.85 [0.69;1.05]), H. influenzae (AOR
= 0.89 [0.73;1.09]) and S. aureus (AOR = 0.92 [0.70;1.19]). By contrast, the carriage rate of M. catarrhalis increased
slightly but not significantly between the 2 periods (AOR = 1.08 [0.95;1.2]). Among Sp carriers, the proportion of
PCV7 vaccine types decreased from 66.6% to 10.7% (P < 0.001), penicillin intermediate-resistant strains increased
from 30.3% to 43.4% (P < 0.001), and penicillin-resistant strains decreased greatly from 22.8% to 3.8% (P < 0.001).
The proportion of Hi ß-lactamase-producing strains decreased from 38.6% to 17.1% (P < 0.001).
Conclusion: The carriage rates of otopathogen species (Sp, Hi, Mc) and Sa did not significantly change in children
with AOM after PCV7 implementation in France. However, we observed significant changes in carriage rates of
PCV7 vaccine serotypes and penicillin non-susceptible Sp.
Background
The nasopharynx is normally colonized with bacteria
such as Streptococcus viridans, nonhemolytic strepto-
cocci, diphtheroids, and Neisseria sp. and potential mid-
dle-ear pathogens such as Streptococcus pneumoniae
(Sp), non-typable Haemophilus influenzae (NTHi) and
Moraxella catarrhalis (Mc) [1]. Furthermore, this
ecosystem is the reservoir for Staphylococcus aureus (Sa)
strains implicated in several infections [2]. The rates of
colonization of these potentially pathogenic species are
heterogeneously reported in the literature. In fact, in
addition to technical procedures of sampling or culture,
many other factors may affect colonization rates: day-
care attendance; respiratory illness, including acute otitis
media (AOM); symptoms of AOM; crowding; season;
siblings; and immunization status [3]. Although Sp,
NTHi, and Mc are part of the normal nasopharyngeal
(NP) flora, increased rate of colonization may identify a
* Correspondence: robert.cohen@wanadoo.fr
1ACTIV, Association Clinique Thérapeutique Infantile du Val de Marne, 27 rue
Inkermann, F94100 Saint Maur des Fossés, France
Full list of author information is available at the end of the article
Cohen et al. BMC Infectious Diseases 2012, 12:52
http://www.biomedcentral.com/1471-2334/12/52
© 2012 Cohen et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.subpopulation of children with increased risk of AOM.
Indeed, frequency of colonization and AOM is highly
correlated (r = 0.37, P < .001) for each pathogen [4].
Furthermore, the disease potential of these pathogens
are not identical. Sp is more frequently associated with
severe AOM (high fever, otorrhea, mastoïditis), pneumo-
nia and invasive diseases and NTHi with conjunctivitis
and recurrent AOM [5,6]. Finally, Mc appears to be the
less pathogenic organism [7].
French authorities recommended routine infant
immunization with 7-valent pneumococcal conjugate
vaccine (PCV7) at age 2, 4 and 12 months for all chil-
dren [8]. The national PCV7 vaccination coverage has
increased slowly and is now relatively high: at least one
dose of PCV7 was received by 69% of children less than
2 years old in 2007, 85% in 2008 and 90% in 2009 as
compared with 62% in 2006 [9].
Before, during, and after PCV7 implementation, sev-
eral studies investigated the impact of PCV7 on pneu-
mococcal and staphylococcal carriage [10-12], but few
have investigated the impact on NTHi and Mc carriage.
Subtle modifications in the equilibrium of NP flora
could lead to different etiological profiles of AOM and
eventually other respiratory tract infections. We aimed
to compare NP carriage of Sp, NTHi, Mc and Sa in
y o u n gc h i l d r e n( 6t o3 0m o n t h s )w i t hA O Mb e f o r ea n d
after PCV7 implementation in France.
Methods
Study design
Before the PCV7 implementation, we performed 4 ran-
domized trials on antibiotic treatment for AOM. These
studies used standardized protocols (including bacterio-
logical NP samples at enrolment), the same inclusion
criteria of AOM [13] and the same age of enrolled chil-
dren [3,14-16]. Furthermore, the studies involved mostly
the same investigators and the same centralized micro-
biology laboratories. These studies allowed us to identify
risk factors for carriage of NP flora bacterial species in
children with AOM and to build a protocol for monitor-
ing the impact of the introduction of PCV7 on this eco-
logical niche [3,12,17-20]. Therefore, for the pre-PCV7
implementation period (1993-2000), we used the dataset
from the 4 randomized trials [3,14-16], and for the post-
PCV7 implementation period (2006- 2009), we used
data from an ongoing surveillance study on the impact
of PCV7 on NP carriage [12,17-20]. To take into
account herd immunity, for the post-PCV7 period, all
children were enrolled regardless of their PCV7 vaccina-
tion status.
The protocols were approved by the Saint Germain en
Laye Hospital Ethics Committee, and written informed
consent was obtained from the parents or guardians.
The inclusion criteria and definitions were the same
during the two periods.
The study populations consisted of children of both
sexes; age 4 to 30 months, with newly diagnosed AOM,
recruited by pediatricians in pediatric outpatient clinics
throughout France. Diagnostic criteria for AOM
included the Paradise algorithm for acute suppurative
otitis media (effusion + marked redness or marked bul-
ging or moderate redness and bulging) [13]. Patients
were not eligible if they had received antibiotic treat-
ment within the 7 days before enrolment. Standardized
history and physical examination findings were
recorded, and information gathered at study entry
included sex, age, daycare modalities, recent antibiotic
treatment (within 3 months before enrolment), history
of AOM, and clinical symptoms and signs of AOM
(thoroughly documented in an identical manner in all
trials). The types of antibiotic treatment used by the
patients in the studies were most commonly amoxicillin-
clavulanate and cefpodoxime proxetil.
Daycare modalities were defined according to those
most frequently used in France:- Children cared for at
home by parents or another person only in the presence
of children belonging to the family.- Children cared for
b yac h i l d c a r eg i v e r ,o u t s i d et h eh o m e ,i nt h ep r e s e n c e
of other children; a maximum of 3 children is author-
ized.- Children cared for in a daycare center, which can
include many children. In general, one room should be
used for the care of no more than 10 children of the
same age.
Upon inclusion, the patients were sampled in order to
identify bacterial pathogens colonizing the NP niche.
Microbiologic investigations
The same methods for NP sampling and microbiological
testing were used in all studies. Deep NP samples were
taken transnasally with use of a flexible, sterile, soft
rayon swab tip. After sampling, swabs were immediately
inoculated in transport medium (Copan Venturi Trans-
ystem, Brescia, Italy), stored at room temperature and
sent within 48 hr to laboratories at the National Refer-
ence Center for Pneumococci at G. Pompidou European
Hospital and to Robert Debré Hospital, in Paris. Swabs
were plated within 24 hr onto chocolate agar, S. aureus
ID agar (SAID; bioMérieux, La Balme Les Grottes,
France) 5% horse blood agar. Agar plates were incubated
at 37°C for 48 hr under 5% CO2 for chocolate and blood
agar. Isolates of Sp, Hi, Mc and Sa were identified using
colony morphology and conventional methods of deter-
mination. S. pneumoniae serotyping and antibiotic sus-
ceptibility testing were performed at the National
Reference Center for Pneumococci. Serotyping was per-
formed using latex particles, which were sensitized with
Cohen et al. BMC Infectious Diseases 2012, 12:52
http://www.biomedcentral.com/1471-2334/12/52
Page 2 of 7antisera purchased from the Statens Serum Institut
(Copenhagen, Denmark). Susceptibility of S. pneumoniae
isolates to penicillin G was determined from minimal
inhibitory concentrations (MICs) by the agar-dilution
method. Isolates were classified as penicillin susceptible
(MIC ≤ 0.06 μg/ml), penicillin non-susceptible (MIC >
0.12 μg/ml), penicillin intermediate resistant (0.12 ≤
MIC ≤ 1.0 μg/ml), or penicillin resistant (MIC ≥ 2 μg/
ml) according to the Clinical and Laboratory Standards
Institute [21]. H. influenzae isolates underwent capsular
serotyping by the slide agglutination method with speci-
f i ca n t i s e r a( P h a d e b a c t ,B o u l eD i a g n o s t i c ,H u d d i n g e ,
Sweden). The production of ß-lactamase was assessed
by a chromogenic cephalosporin test (Nitrocefin; Cefi-
nase; Biomerieux, Marcy l’Etoile, France). H. influenzae
strains were further classified as ampicillin susceptible
(MIC ≤ 1 mg/L) or resistant (MIC > 1 mg/L).
Statistical analyses
Data were double-entered using 4D software (version
6.4), and analysed using Stata SE 9.1 (Stata Corp., Col-
lege Station, TX, USA) for univariate analysis and multi-
variate logistic regression (adjusted odds ratios [AORs]
and 95% confidence intervals [CI]). For the descriptive
statistics, we used mean and median age (months) of
children. The Pearson chi-square test was used to com-
pare NP carriage of pneumococci, Hi, Mc and Sa before
and after PCV7 implementation. Factors related to NP
carriage were identified by univariate analysis (p < 0.20,
Pearson chi-square test). These variables, included in
multivariate logistic regression models were daycare
attendance, recent antibiotic treatment (within 3 months
before enrolment), fever ≥ 38.5°C, conjunctivitis, otalgia,
and carriage of pneumococci, H. influenzae, M. catar-
rhalis and S. aureus. These models were systematically
adjusted on the period of study (before and after PCV7
implementation) and on age dichotomized as < 12 and
≥ 12 months. The cut-off of 12 months was chosen for
regression model for several reasons: the vaccination
schedules differ before and after this age (reflecting the
immunity maturation), in many studies, the NP carriage
is higher after 12 months, and in one of our studies,
young age (< 12 months) predicted penicillin non sus-
ceptible pneumococci carriage [19].
Results
Study population
The total study population consisted of 4,405 children
(mean age 13.9 months, median 12.8): 1,807 were
enrolled before PCV7 implementation and 2,598 after.
Among the latter group, 98.3% were PCV7 vaccinated.
Less than 1% of children had received only one dose of
PCV7, and 98.6% were correctly vaccinated for age.
Table 1 describes the demographic and clinical charac-
teristics of the 2 populations. Fever (> 38.5°C) and day-
care center attendance were more frequent after than
before PCV7 implementation. The mean and the med-
ian age were slightly higher in the pre-PCV7 period,
however, these differences did not exceed 1 month.
Otalgia and antibiotic use before enrolment were signifi-
cantly more frequent before than after PCV7 implemen-
tation, with no significant change in type of antibiotic
prescribed 3 months before enrolment.
NP colonization in the pre-and post-PCV7 periods
Table 2 presents the carriage rates of Sp, Hi, Mc and
Sa before and after PCV7 implementation. Almost all
Hi strains were non-typeable (98.5%). The carriage
rates of Sp, NTHi and Sa did not differ between the 2
periods, but Mc carriage increased (5%). The Figure 1
Table 1 Demographic and clinical characteristics of children with acute otitis media (AOM) before and after 7-valent
pneumococcal conjugate vaccine (PCV7) implementation in France
Child characteristics Before PCV7 n = 1.807 (%) After PCV7 n = 2,598 (%) p-value
Male sex’ 970 (53.7) 1,376 (53.0) 0.6
Age (months), mean ± SD 14.6 ± 7.6 13.8 ± 5.1 < 0.0001
Median 12.8 13.1
Type of care < 0.0001
Daycare center 436 (24.1) 1032 (39.7)
Child caregiver 530 (29.3) 811 (31.2)
Home 841 (46.6) 754 (29.1)
Antibiotics 3 months before enrolment 336 (57.2)* 1243 (47.9) < 0.0001
Conjunctivitis 436 (24.1) 652 (25.1) 0.5
Otalgia 1304 (83.0)** 1945 (75.0) < 0.0001
Fever (≥ 38.5°C) 671 (37.1) 1551 (60.3) < 0.0001
* available for 587 patients
** available for 1,571 patients
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PCV7 implementation. Among the Sp carriers, the pro-
portion of PCV7 vaccine types (serotypes 4, 6B, 9 V,
1 4 ,1 8C ,1 9Fa n d2 3F )d e c r e a s e df r o m6 6 . 6 %t o
10.7% (P < 0.001), penicillin intermediate-resistant
strains increased from 30.3% to 43.4% (P < 0.001), and
penicillin-resistant strains greatly decreased from
22.8% to 3.8% (P < 0.001). The proportion of Hi ß-
lactamase-producing strains decreased from 38.6% to
17.1% (P < 0.001).
Risk factors for carriage of S. pneumoniae, NT H.
influenzae, M. catarrhalis, and S. aureus
We analyzed the factors influencing Sp, NTHI, Mc and
Sa carriage by logistic regression analysis (Table 3) and
found the following:
Table 2 Nasopharyngeal carriage of Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis and
Staphylococcus aureus in children with AOM before and after PCV7 implementation
Carriage Before PCV7 n = 1807 (%) After PCV7 n = 2598 (%) p-value*
S. pneumoniae 1047 (57.9) 1510 (58.1) 0.9
PCV7 vaccine types 402/604**(66.6) 162 (10.7) 0.0001
Penicillin intermediate- resistant 317 (30.3) 656 (43.4) 0.0001
Penicillin resistant 239 (22.8) 58 (3.8) 0.0001
Non-typable H. influenzae 849 (47) 1269 (48.8) 0.2
ß-lactamase+ 328 (38.6) 217 (17.1) 0.0001
M. catarrhalis 939 (52) 1479 (56.9) 0.001
S. aureus 112 (6.2) 136 (5.2) 0.2
Multiple carriage (≥ 2 species) 978 (54.1) 1502 (57.8) 0.02
No carriage 133 (7.4) 187 (7.2) 0.8
* Chi square test
** on available serotypes
Figure 1 Distribution of serotypes before and after 7-valent pneumococcal conjugate vaccine (PCV7) implementation.
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associated with a reduction of Sp, NTHi and Mc carriage.
By contrast, Mc carriage was associated with an increased
risk of Sp carriage (AOR = 1.23, 95% CI [1.08; 1.39]).
In comparing the pre- and post-PCV7 periods, we
found a slight but non-significant decrease in carriage
rates of pneumococcus (AOR = 0.85 [0.69;1.05]), H.
influenzae (AOR = 0.89 [0.73;1.09]) and S. aureus (AOR
= 0.92 [0.70;1.19]). By contrast, the carriage rate of M.
catarrhalis increased slightly but not significantly
between the 2 periods (AOR = 1.08 [0.95;1.2]).
Table 3 Risk factors for carriage of S. pneumoniae, non-typable (NT) H. influenzae, M. catarrhalis, and S. aureus by
univariate and multivariate analysis
Univariate analysis Multivariate analysis*
OR [95% CI] P value OR [95% CI] P value
Carriage of S. pneumoniae
Fever ≥ 38.5°C 1.47 1.30;1.66 < 0.0001 1.3 1.11;1.54 0.002
Daycare centre attendance 1.45 1.28;1.65 < 0.0001 1.51 1.28;1.78 < 0.0001
Carriage of M. catarrhalis 1.41 1.25;1.59 < 0.0001 1.17 1.01;1.36 0.034
Period of the study 1.01 0.89;1.14 0.905 0.85 0.69;1.05 0.130
Age ≥ 12 months 0.99 0.88;1.11 0.853 0.94 0.81;1.09 0.392
Antibiotic use 3 months before enrolment 0.80 0.69;0.92 0.002 0.76 0.66;0.89 < 0.0001
Carriage of H. influenzae 0.80 0.71;0.90 < 0.0001 0.84 0.72;0.98 0.028
Conjunctivitis 0.50 0.43;0.57 < 0.0001 0.52 0.44;0.62 < 0.0001
Carriage of S. aureus 0.36 0.27;0.46 < 0.0001 0.49 0.35;0.67 < 0.0001
Carriage of NT H. influenzae
Conjunctivitis 4.64 3.98;5.42 < 0.0001 4.39 3.67;5.26 < 0.0001
Daycare centre attendance 1.63 1.44;1.85 < 0.0001 1.40 1.18;1.65 < 0.0001
Age ≥ 12 months 1.43 1.27;1.62 < 0.0001 1.28 1.10;1.48 0.001
Antibiotic use 3 months before enrolment 1.27 1.10;1.46 0.001 1.22 1.05;1.42 0.01
Period of the study 1.08 0.96;1.22 0.224 0.89 0.73;1.08 0.261
Carriage of S. pneumoniae 0.80 0.71;0.90 < 0.0001 0.83 0.71;0.96 0.015
Carriage of S. aureus 0.47 0.35;0.62 < 0.0001 0.61 0.43;0.85 0.004
Carriage of M. catarrhalis
Daycare centre attendance 1.91 1.68;2.17 < 0.0001 1.83 1.60;2.09 < 0.0001
Carriage of S. pneumoniae 1.41 1.25;1.59 < 0.0001 1.23 1.08;1.39 0.001
Fever ≥ 38.5°C 1.30 1.15;1.46 < 0.0001 1.17 1.03;1.33 0.015
Period of the study 1.22 1.08;1.38 0.001 1.08 0.95;1.22 0.255
Age ≥ 12 months 1.14 1.01;1.28 0.037 1.05 0.93;1.19 0.424
Conjunctivitis 0.79 0.68;0.90 0.001 0.77 0.67;0.89 < 0.0001
Carriage of S. aureus 0.40 0.31;0.52 < 0.0001 0.44 0.33;0.58 < 0.0001
Carriage of S. aureus
Carriage of S. pneumoniae 0.36 0.27;0.47 < 0.0001 0.35 0.26;0.46 < 0.0001
Carriage of H. influenzae 0.47 0.35;0.62 < 0.0001 0.43 0.33;0.57 < 0.0001
Carriage of M. catarrhalis 0.40 0.31;0.52 < 0.0001 0.42 0.32;0.55 < 0.0001
Age ≥ 12 months 0.61 0.47;0.79 < 0.0001 0.65 0.50;0.85 0.002
Period of the study 0.84 0.65;1.08 0.173 0.92 0.70; 1.19 0.521
OR = odds ratio; 95% CI = 95% confidence interval.
*Tested variables in the regression logistic model were: period of the study, age, daycare attendances modalities, conjunctivitis, fever ≥ 38.5°C, otalgia, antibiotic
3 months before inclusion, Sp, Hi, Bc and Sa carriage. Only variables kept in the final model are presented in the table.
- Daycare center attendance was associated with increased carriage rates of Sp, NTHi and Mc.
- Age > 12 months was associated with increased NTHi carriage and with decreased Sa carriage.
- Fever ≥ 38.5°C was associated with an increased risk of Sp carriage.
- Conjunctivitis was associated with an increased risk of NTHi carriage and a decreased risk of Sp carriage.
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In this study, we studied NP samples of children with
AOM before and after PCV7 implementation in France
and found a marked reduction in vaccine serotype car-
riage after PCV7 implementation.
However, the overall pneumococcal, H. influenzae and
S. aureus carriage slightly decreased but non signifi-
cantly. These results agree with those from 2 prospec-
tive studies comparing vaccinated and non-vaccinated
populations, one enrolling HIV-infected and HIV-unin-
fected children 5 years after completion of immuniza-
tion in South Africa [22] and the other a randomized
controlled trial of the impact of 2 doses and 2 + 1 doses
of PCV7 on carriage of Sp, Hi and Mc in normal chil-
dren in The Netherlands [22,23]. Reduced-dose PCV7
schedules slightly reduced overall pneumococcal carriage
but not carriage of Hi and Mc [22,23]. The vaccination
coverage reported in our study (> 98% in 2006-2009) is
higher than that for all children in France (91%) [9].
H o w e v e r ,t h ei n v e s t i g a t o r si nt h i ss t u d yw e r ew e l l -
trained pediatricians, and the vaccination coverage is
higher in France for children followed by pediatricians
than general practitioners.
Post-licensure studies of middle ear fluid of patients
with AOM after PCV7 implementation in the United
States have shown a relative increase in H. influenzae-
and M. catarrhalis-positive middle-ear fluid cultures,
together with decreased pneumococcal and vaccine ser-
otype AOM. These were ecological and uncontrolled
observations and do not necessarily represent true
increases in otitis media due to non-pneumococcal
pathogens [24]. The reduction of ß-lactamase-producing
NTHi strains is probably due to the overall reduction in
antibiotic prescriptions in France with the Health
Authorities promotional campaign for appropriate anti-
biotic prescription [25,26]. In fact, the most prescribed
antibiotics for AOM (leading reason for antibiotic pre-
scriptions for infants and toddlers) were cefpodoxime
proxetil and amoxicillin-clavulanate [25]. Under these
selective pressures, ß-lactamase-producing NTHi strains
have no ecological advantage. Of note, these regimens
could lead to increased ß-lactamase-negative ampicillin-
resistance strains in France [27].
Our study has several limitations. The dataset used for
the pre-PCV7 period combined the results of 4 different
studies performed during 7 years. Because of the relative
heterogeneity of the results, several epidemiological and
clinical characteristics (daycare attendance, antibiotics,
fever or otalgia) that might influence carriage rates sig-
nificantly differed between the 2 periods, which necessi-
tated multivariate analysis. Also data for some clinical
and demographic features were missing in the pre-PCV7
period. Finally, data that may also influence carriage
rates, such as crowding or siblings, were not recorded
before and after PCV7 implementation.
Recently available pneumococcal conjugate vaccines
with broader serotype coverage may lead to reduced
overall pneumococcal carriage; the impact on the car-
riage of other NP pathogens requires on-going
monitoring.
Conclusions
After implementation of PCV7 vaccine in France, no
significant changes in NP carriage with S. pneumoniae,
H. influenzae, M. catarrhalis and S. aureus were
observed in children with AOM. Effects over time with
high-vaccine pressure following nationwide implementa-
tion of pneumococcal conjugate vaccines with broader
serotype coverage need to be followed.
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